NCT04750317View on ClinicalTrials.gov

Efficacy and Safety of Tofacitinib in Patients With COVID-19 Pneumonia

PHASE2CompletedINTERVENTIONAL
Enrollment

414

Participants

Timeline

Start Date

May 11, 2020

Primary Completion Date

August 1, 2020

Study Completion Date

September 1, 2020

Conditions
COVID-19
Interventions
DRUG

Tofacitinib

Tofacitinib was administered at a dose 10 mg twice daily on day 1, followed by 5 mg twice daily on day 2-5. The dosage was reduced up to 5 mg once daily in patients with moderate renal impairment or moderate hepatic impairment.

Trial Locations (1)

119991

Sechenov First Moscow State Medical University (Sechenov University) - University Clinical Hospital, Moscow

All Listed Sponsors
lead

I.M. Sechenov First Moscow State Medical University

OTHER

NCT04750317 - Efficacy and Safety of Tofacitinib in Patients With COVID-19 Pneumonia | Biotech Hunter | Biotech Hunter